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ABSTRACT 
 
INTRODUCTION 
 
Only a minority of esophageal cancers demonstrates a pathological tumor 
response (pTR) to neoadjuvant chemotherapy (NAC). 18F-fluorodeoxyglucose 
(FDG) positron emission tomography-computed tomography (PET-CT) is often 
used for restaging after NAC and to assess response. Increasingly, it is used 
during therapy to identify unresponsive tumors and predict pTR , using avidity of 
the primary tumor alone. However, definitions of such metabolic tumor 
response (mTR) vary. We aimed to comprehensively re-evaluate metabolic 
response assessment using accepted parameters, as well as novel concepts of 
metabolic nodal stage (mN) and nodal response (mNR).  
 
PATIENTS AND METHODS 
This was a single-center retrospective UK cohort study. All patients with 
esophageal cancer staged before NAC with PET-CT and after with CT or PET-CT 
and undergoing resection from 2006-2014 were identified. pTR was defined as 
Mandard tumor regression grade 1-3; imaging parameters included metrics of 
tumor avidity (standardized uptake value [SUV]max/mean/peak), composites of 
avidity and volume (including metabolic tumor volume), nodal SUVmax, and our 
new concepts of mN stage and mNR. 
 
RESULTS 
Eighty-two (27.2%) of 301 patients demonstrated pTR. No pre-NAC PET 
parameters predicted pTR. In 220 patients re-staged by PET-CT, The optimal 
tumor ΔSUVmax threshold was a 77.8% reduction. This was as sensitive as the 
current PET Response Criteria in Solid Tumors (PERCIST) 30% reduction, but 
more specific with a higher negative predictive value (p<0.001). ΔSUVmax and 
Δlength independently predicted pTR, and composite avidity/spatial metrics 
outperformed avidity alone. Whilst both mTR and mNR were associated with 
pTR, in 82 patients with FDG-avid nodes before NAC we observed mNR in 10 
(12.2%) not demonstrating mTR.  
 
 
CONCLUSION 
Current definitions of metabolic response are suboptimal and too simplistic. 
Composite avidity/volume measures improve prediction. mNR may further 
improve response assessment, by specifically assessing metastatic tumor sub-
populations, likely responsible for disease relapse, and should be urgently 
assessed when considering aborting therapy on the basis of mTR alone. 
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INTRODUCTION 
 
In the USA and Europe the mainstay of curative treatment of esophageal cancer 
is neoadjuvant chemotherapy (NAC) or chemoradiotherapy (NACR) followed by 
surgery (1,2). Both confer important survival benefits (3); however, up to 60% of 
tumors show either minimal or no pathological response (pTR) to NAC (4,5), and 
a similarly poor response is seen in 30-40% after NACR(6). For these patients, 
such, in retrospect, futile therapy delays surgery, potentially allowing disease 
progression and a worse prognosis (7). The ability to predict pTR at the outset 
would therefore be invaluable, as it would allow personalized therapy, with 
neoadjuvant therapy being omitted or changed to alternative therapy in those 
patients unlikely to benefit.  
 
The evidence for the predictive value of baseline molecular markers and 
positron emission tomography (PET) is insufficiently robust to justify major 
treatment changes (8,9). Interval assessment of response during therapy is, 
therefore, the next best option for personalizing therapy. Interval tumor 
metabolic response (mTR) on PET predicts pTR, albeit imperfectly. A 35% 
reduction in maximum standardized uptake value (SUVmax) is most commonly 
used during therapy (10,11) , and formed the basis of the landmark MUNICON 
trial, wherein NAC was continued after a single cycle only in patients with a 
reduction in SUVmax greater than 35% (12); the alternative PERCIST criteria 
recommend a 30% reduction after NAC to define mTR (13). However, these 
thresholds may not be optimal: PERCIST is neither tumor nor context-specific, 
whilst the MUNICON threshold was derived from just 40 patients; furthermore, 
SUVmax provides no spatial information. More fundamentally, both assess only 
the primary tumor; the high rates of disease recurrence seen even in patients 
with pathologically responsive primary tumors, suggests important unidentified 
factors, perhaps involving nodal or distant micrometastases—a recent report 
described tumor down-staging after NAC (a reduction from pre-treatment 
clinical to post-treatment pathological stage) to be strongly associated with 
survival (14). 
 
With this in mind, we recently explored the novel concepts of FDG-avid 
nodal stage (mN stage) and metabolic nodal response (mNR), and 
demonstrated major clinical implications for identifying disease progression 
during NAC, independent of primary tumor stage and response (15).  
 
In this study we aimed to re-examine comprehensively the utility of PET-CT 
in predicting pTR to NAC.  Firstly, we assessed the predictive ability of clinical, 
pathological and imaging factors available before NAC. Secondly, we aimed to 
define and compare optimal thresholds of mTR after NAC and assess, for the 
first time, the novel concept of mNR. Thirdly, we aimed to generate and validate 
predictive models that might have clinical utility.  
 
METHODS 
 
Patients and staging protocol 
 
All patients who underwent potentially curative surgical resection of 
esophageal/gastroesophageal junctional cancer and were staged initially with 
computed tomography (CT) and 18F-fluorodeoxyglucose (FDG) PET-CT were 
identified from a departmental database (May 2006-November 2014) (16). This 
included all cell types. The study was approved by the institutional clinical 
governance department, and the need for written informed consent was waived. 
Patients were also staged with endoscopic ultrasound, and laparoscopy for 
tumors extending below the diaphragm as previously described (16). 
Examinations were reported by a consultant upper gastrointestinal 
radiologist/gastroenterologist using the contemporary American Joint 
Committee on Cancer TNM staging manual (6th (17) or 7th edition (18)). 
 
Neoadjuvant chemotherapy 
 
NAC was considered for all patients with disease more advanced than 
T1N0. Patients with esophageal and GEJ Siewert 1/2 tumors (19) received either: 
cisplatin and 5-fluorouracil (5-FU; 2 cycles; n=182)(20), oxaliplatin and 5-FU (2 
cycles; n=46) (21), epirubicin, cisplatin and 5-FU (ECF; 3 cycles; n=7), epirubicin, 
cisplatin and capecitabine (ECX; 3 or 4 cycles; n=22) (22), epirubicin, oxaliplatin 
and capecitabine (EOX; 3 cycles; n=3), cisplatin and etoposide (2 cycles; n=1) or 
oxaliplatin and capecitabine (2 cycles; n=1). Patients with type 3 GEJ tumors 
received ECX/EOX/ECF (3 cycles). Some patients (distal esophageal/GEJ) 
received 3 cycles of ECX pre-and post-operatively with (n=7) or without 
bevacizumab (n=20) (23), or 3 cycles of ECF pre- and post-operatively (n=12) 
(24). 
 
Restaging CT and PET-CT  
 
Patients were re-staged 4-6 weeks after NAC using CT before 2008 and PET-CT 
afterwards (although a small minority underwent CT due to clinical trial 
protocols) as previously described (16). 18F-FDG PET-CT was performed using 
one of two scanners. Before 3rd November 2009 scans were performed on a GE 
Discovery STE (GE Healthcare,Milwaukee, USA) 60 minutes post-injection of 
400MBq 18F-fluorodeoxyglucose (FDG). Images were reconstructed using a time 
of flight ordered subset expectation maximization reconstruction algorithm (two 
iterations, 20 subsets, 70cm field of view, 128 matrix, voxel size 5.47x5.47x3.3 
mm3). After 3rd November 2009, scans were performed on a GE Discovery 690 
(GE Healthcare,Milwaukee, USA) 90 minutes post-injection of 4MBq/Kg FDG. 
Images were reconstructed using a time of flight ordered subset expectation 
maximization reconstruction algorithm (two iterations, 24 subsets, 6.4mm 
Gaussian filter, 70cm field of view, 256 matrix, voxel size 2.73x2.73x3.3 mm3). 
Examinations were independently reported by 2 dedicated PET-CT radiologists.  
 
 
Operations 
 
Surgery was typically performed within 2 weeks of re-staging scan. A 
minimum two-field lymphadenectomy was performed as standard. 
 
Data and variables  
 
Patient variables included age, gender, and American Society of 
Anesthesiologists grade (25); pre-treatment tumor variables were cell type, 
grade (26), anatomical site, T (7th edition), N stage (6th edition as data were 
insufficient for conversion to the 7th), and whether the tumor was impassable at 
esophago-gastroduo-denoscopy. PET-CT variables are described below. NAC 
variables comprised dual or triple agent regimen (due to large number of 
regimens and small patient groups), and time (days) from staging to restaging 
scan and scan to surgery to adjust for delays and number of cycles given. pTR 
was defined as Mandard Tumor Regression Grade (TRG) ≤3, following dedicated 
review by a consultant cellular pathologist (27). The Mandard TRG was used in 
preference to alternative TRGs, being the most frequently used TRG for 
esophageal cancer (28), with optimal prediction of survival (29,30).  
 
PET-CT variables 
 
Variables comprised primary tumor FDG-avidity (SUVmax and length 
[cm]), mN stage, mNR and SUVmax of the most FDG-avid node. The 
development of mN stage and mNR have been described previously (15). mN 
stage (nodes visible discretely from the tumor, within a standard 
lymphadenectomy territory, with SUVmax>2.5 or background mediastinal blood 
pool) comprised mN0 (0 avid nodes), mN1 (1-2 nodes) and mN2 (>2 nodes). 
mNR comprised complete (CMR), or partial metabolic response (PMR; reduction 
in mN or SUVmax ≥30%), stable (SMD; stable mN or reduction/progression 
SUVmax <30%) or progressive metabolic disease (PMD; progression of mN or 
SUVmax ≥30%.  
 
For examinations using the second PET-CT scanner, additional variables 
were generated by two authors: metabolic tumor volume (MTV), SUVmean, 
SUVpeak, and tumor glycolytic volume (TGV)mean/max. MTV was measured 
using a fixed threshold technique (SUV≥4). TGVmean was calculated manually as 
the product of MTV and SUVmean. TGVmax was calculated as the product of 
MTV and SUVmax.  mTR was quantified using absolute changes (∆%) and 
thresholds defined previously (PET Response Criteria in Solid Tumors [PERCIST} 
and MUNICON criteria; SUVmax) (13); additionally, new thresholds were 
generated by receiver operator characteristics (ROC).  
 
Statistical analysis 
 
Analysis was performed using R v3.0.2 (31). Correction for multiple 
comparisons was performed using the Bonferroni method (32) or false discovery 
rate using FDRtoolv1.2.12 (33). For regression continuous variable distribution 
was assessed using density plots and transformed (age2; logSUVmax/mean/peak 
and time to re-staging/surgery). Multivariate analysis included all variables 
(including PET-CT scanner) after exclusion of perfect separators. ROC optimal 
thresholds were calculated and compared with pROC (34); 95% confidence 
intervals (CI) using 200 iterations of 0.632 bootstrapping. Sensitivies and 
specificities were compared using McNemar’s test (DTComPair v1.0.3) (35). 
 
Model development, tuning, validation and performance 
 
Three techniques were used as previously described (16): logistic 
regression (backwards stepwise binary logistic), decision tree analysis (recursive 
partitioning using loss matrices) and artificial neural networks (feed forward 
back-propagation multilayer perceptron). Models were tuned, generated and 
validated internally (0.632 bootstrapping) using a development group (patients 
staged/restaged using the more recent scanner) and validated independently 
(patients staged/restaged using the earlier scanner; validation group). We 
partitioned patients in this way to minimize any potential bias, to ascertain 
immediate clinical utility, and also to assess generalizability to a different scanner 
system. 
 
RESULTS  
 
Three-hundred-and-two patients underwent resection following NAC. TRG 
was available for 301 (table 1). pTR was evident in 82 patients (27.2%): TRG 1 in 14 
(4.65%); TRG 2 in 13 (4.32%); TRG 3 in 55 (18.3%); TRG 4 in 162 (53.8%); TRG 5 in 
67 (22.2%). 
 
Predicting pathological response before NAC 
 
Although there were nominally significant associations between tumor 
anatomical location and response, on multivariate regression, the only variable 
that predicted pTR was the use of a triple agent NAC regimen: OR 5.98 (CI 2.44-
14.7; p=8.94x10-5; Table 2).  
 
Predicting pathological response after NAC using absolute PET variables 
 
A more FDG-avid primary tumor after NAC, as quantified by all metrics, 
was negatively associated with pTR: logSUVmax OR 3.84x10-4 (1.17x10-5-2.00x10-3; 
p=9.89x10-6 (Table 3; Supplementary Table 1).  
 
Predicting pathological response using metabolic tumor response 
 
mTR predicted pTR (tables 1 and 4; Supplementary Table 2). This was true 
both for ΔSUVmax and Δlength, independently on regression: logΔSUVmax OR 
for each % reduction 1.03 (1.01-1.06), p=3.24x10-3; Δlength OR=1.02 (1.00-1.03); 
p=0.019. Interestingly, whilst a PERCIST ≥30% reduction was associated with pTR, 
the MUNICON ≥35% threshold was not, once adjusted for Δlength. All additional 
metrics of mTR were associated with pTR. 
 
Predicting pathological response using metabolic nodal response 
 
mNR was associated with pTR using Fisher’s exact test (Table 1, but not on 
multivariate regression (Table 4).  Notably, mNR and pTR were discordant in 
42/220 (19.1%) patients (Table 5). In 41 cases there was a nodal CMR or PMR 
without pTR, representing 51.2% of the 82 patients with FDG-avid nodes before 
NAC (Table 5).  
 
mTR and mNR were also compared (Table 5) and were found to be 
discordant in 13 (5.90%) cases overall, representing 15.9% of patients with FDG-
avid nodes before NAC. Typically discordance arose due to a mNR in the 
absence of mTR (10 cases; 4.6% and 12.2% respectively).  
 
Defining optimal metabolic response thresholds 
 
The accuracy of each continuous (non-threshold) metric of mTR in 
predicting pTR is shown in Supplementary Table 3: all were moderately 
discriminant (80.2-84.4%), with no statistically significant differences.  
 
The optimal thresholds for each metric of mTR were determined 
(supplementary Table 3), for (a) discrimination (b) sensitivity and (c) specificity. 
The optimal Δ SUVmax for sensitivity was a 27.4-30.6% reduction, identical to 
PERCIST (30%) and similar to the MUNICON threshold (35%). However, 
specificity was minimal: 33.0% (23.8-42.6); 41.8% (32.0-52.2) respectively. By 
contrast, the optimal ΔSUVmax threshold for balancing sensitivity (73.6% [58.6-
82.7]) and specificity (84.5% [78.7-89.1]) was dramatically different: a 77.8% 
reduction. Rounded down to a more pragmatic 75.0%, sensitivity was identical, 
whilst specificity reduced slightly to 84.0%. 
 
The ability of each mTR metric to predict pTR is shown in Supplementary 
Tables 4-6. Overall, ΔSUVmax of 77.8%, was significantly more discriminant, with 
higher negative predictive value (NPV), than the PERCIST (30%) and MUNICON 
(35%) thresholds. The same was true for ΔMTV, ΔTGVmax and ΔTGVmean. The 
highest sensitivities were seen with PERCIST (sensitivity 100%), MUNICON 
(97.1%), ΔMTV (97.1%), ΔTGVmax (97.1%) and ΔTGVmean (94.3%); these were 
significantly more sensitive than Δlength (<4.68x10-3; FDR=0.046), but not 
ΔSUVmax of 77.8%. The most specific were ΔSUVmax of 77.8% (81.7% specific) 
and Δlength of 53.1% (82.7%) (p<4.11x10-4).  
 
Performance of predictive models 
 
Models were generated (supplementary table 7) using metrics of 
mTR/mNR. The most successful was a logistic regression model comprising 
Δlength + ΔSUVmax; this was highly sensitive (91.4%), moderately specific 
(71.4%) and discriminant (0.814) and this sensitivity persisted during internal and 
independent validation (although with relatively poor specificity and 
discrimination). However, ultimately none of the composite models 
outperformed individual mTR thresholds (Supplementary Tables 4-7).  
 
DISCUSSION 
 
In this study of 301 patients treated with NAC and surgery—the largest to 
date in esophageal cancer —we found no baseline clinical, tumor or PET 
variables associated with pTR. This is perhaps unsurprising, reflecting the 
daunting complexity involved.  ‘Chemoresistance’ is usually multifactorial and 
constitutes a spectrum of sensitivity, which depends upon numerous 
macroscopic, microscopic and molecular factors modulating chemotoxicity 
(36,37). Intratumoral heterogeneity further complicates this, with a number of 
subclones, potentially demonstrate differential response and baseline 
characteristics, in addition to heterogeneity between tumor and nodal 
metastases. In contrast, following NAC, a number of PET variables, including 
absolute tumor metrics and those assessing either mTR or mNR, were strongly 
associated with pTR on multivariate analysis, and a number of clinically relevant 
implications were identified.  
 
Firstly, the identification of a significantly better ΔSUVmax threshold 
(77.8% reduction) than the generic PERCIST threshold (30%) suggests that the 
latter should be raised considerably for esophageal cancer to improve 
stratification of mTR (perhaps to a more pragmatic 75%). This threshold was 
nominally significantly better than the MUNICON threshold (35%), but as this 
threshold was originally derived during therapy rather than after therapy (as in 
our study), the significance of this is uncertain and we are unable to draw further 
conclusions.  
 
Secondly, rather than considering avidity in isolation, we found evidence 
that incorporating spatial data improved prediction: Δlength at a most basic 
level, or ideally a composite metric such as ΔMTV or ΔTGVmax/mean. These 
outperformed the existing recommended PERCIST threshold of a 30% SUVmax 
reduction. They were comparably sensitive, but more specific (p<4.11x10-4) and 
discriminant (p<9.38x10-5) and were supported by internal (bootstrapping) 
validation. This suggests that composite metrics may have greater predictive 
ability in clinical trials than ΔSUVmax alone (such as in the MUNICON trial 35% 
threshold). In particular, their superior specificity and high NPV (98.5-100%) 
might identify more non-responders suitable for cessation of therapy. These 
findings are in keeping with those of recent smaller studies in 
chemoradiotherapy; in 20 patients using support vectors and logistic regression, 
Zhang et al found mTR quantified using spatial avidity metrics outperformed 
avidity alone in predicting pTR (38); whilst in 37 patients Jayachandran et al 
found MTV to outperform SUVmax (39).  
 
Thirdly, this is the first study to assess the novel concept of mNR in 
association with pTR. We found that the primary tumor and nodal disease often 
demonstrated a discordant response to NAC, with mNR seen in the absence of 
mTR or pTR. Using mTR alone (as in the MUNICON trial), this subgroup of 
patients would be classed as ‘non-responders’ and NAC aborted; our findings 
suggest that in such patients their nodal metastases may in fact be responding 
to treatment. Nodal metastases by definition contain an aggressive 
subpopulation of cancer clones originating from the primary tumor, which then 
evolve differently at a genetic and phenotypic level(40). A crucial such 
phenotype is chemosensitivity. Whilst clearly mNR is likely an imperfect 
surrogate of pathological nodal response, no systems for assessing nodal 
response are in use.  Our findings are important, as they offer a vital insight into 
assessing response in the tumor subclones with proven metastatic behavior, 
likely to be responsible for local and distant disease relapse. 
 
This study has a number of limitations. Whilst the current gold-standard 
technique for disease response assessment is direct histopathological 
examination, this remains imperfect. We used the Mandard classification, which 
originally described the response of esophageal squamous cell carcinoma to 
cisplatin-based NACR (27). The Mandard TRG has subsequently been validated 
for esophageal adenocarcinoma (41) although a number of other classifications 
have been described (42); all, however, remain relatively subjective, and are 
tempered by potential inter-observer variability, and intra-tumoral sampling bias 
(43). Ultimately, the Mandard TRG is most frequently used and provides the 
basis for optimal prediction of survival (28,30). An additional limitation of this 
study is its retrospective design over a long time period, which whilst necessary 
to generate a sufficient cohort resulted in a change of PET-CT scanner, and the 
availability of additional metrics for the more recent scanner alone. In addition, 
we included a range of cell types, rather than restricting our analysis. We sought 
to mitigate these limitations with dedicated review of TRG by a single expert 
pathologist, by adjusting analyses for cell type, the scanner used, and by 
restricting model development to the more recent representative scanner with 
subsequent validation in the earlier group, in order to minimize any bias. We 
also performed a post hoc analysis comparing metrics between scanners, 
demonstrating no significant differences in either metabolic response of the 
primary or nodal tumor (p=0.109 [Mann-Witney] and 0.068 [Fisher’s exact test]). 
We believe this to be the largest study performed for esophageal cancer and 
believe that our results are robust—whether they can be extrapolated to NACR 
is not clear, but we believe warrants urgent assessment. In addition, assessment 
of a number of textural response parameters, including entropy and run-length 
matrices, which whilst not routinely used in clinical practice have recently been 
shown to be associated with pTR following NACR (44), and their inclusion in 
conjunction with volume has been suggested to improve prognostication (45). 
Such metrics may therefore provide complementary predictive data. 
 
In conclusion, we found that the current definitions used for metabolic 
response assessment after NAC, based solely on ΔSUVmax, are both suboptimal 
and too simplistic, and that using composite measures of FDG-avidity and 
volume could significantly improve the predictive ability of PET. The assessment 
of nodal response, which is often discordant with the primary tumor response, 
should be urgently studied, as it may offer the potential to further improve 
response assessment, specifically within tumor populations with proven 
metastatic behavior. 
  
Table 1: Patient characteristics and management and tumor response 
Baseline factor Overall (n=301) Pathological response 
(n=82) 
No pathological 
response (n=219) 
p 
α=4.55x10-3 pre-NAC 
α=2.63x10-3 post-
NAC 
Age 
Median; IQR; range 
64.0  
(58.0-70.0; 36.0-80.0) 
62.5  
(57.3-69.0; 36.0-79.0) 
64.0  
(58.0-70.0; 38.0-80.0) 
0.369a 
Gender 
Male 
Female 
 
228 (75.7%) 
73 (24.3%) 
 
61 (74.4%) 
21 (25.6%) 
 
167 (76.3%) 
52 (23.7%) 
 
0.764b 
Cell type 
AC 
SCC 
AS 
NEC 
SC 
Anaplastic 
 
249 (82.7%) 
44 (14.6%) 
5 (1.66%) 
0 (0.00%) 
1 (0.33%) 
2 (0.66%) 
 
68 (82.9%) 
13 (15.9%) 
1 (1.22%) 
0 (0.00%) 
0 (0.00%) 
0 (0.00%) 
 
181 (82.6%) 
31 (14.2%) 
4 (1.83%) 
0 (0.00%) 
1 (0.46%) 
2 (0.91%) 
 
0.979 b 
Grade of differentiation 
Well 
Moderate 
Poor  
Undifferentiated 
 
28 (9.30%) 
128 (42.5%) 
140 (46.5%) 
5 (1.66%) 
 
5 (6.10%) 
35 (42.7%) 
42 (51.2%) 
0 (0.00%) 
 
23 (10.5%) 
93 (42.0%) 
98 (44.7%) 
5 (2.28%) 
 
0.338b 
Tumor site 
Proximal 1/3 
Mid 1/3 
Distal 1/3 
GEJ 1 
GEJ 2 
GEJ 3 
Multifocal 
 
0 (0.00%) 
18 (5.98%) 
52 (17.3%) 
72 (23.9%) 
107 (35.5%) 
51 (16.9%) 
1 (0.33%) 
 
0 (0.00%) 
9 (11.0%) 
11 (13.4%) 
23 (28.0%) 
20 (24.4%) 
19 (23.2%) 
0 (0.00%) 
 
0 (0.00%) 
11 (5.02%) 
41 (18.7%) 
49 (22.4%) 
85 (38.8%) 
32 (14.6%) 
1 (0.46%) 
 
0.033 b 
Pre-NAC staging    
T stage 
1 
2 
3 
4a 
4b 
 
7 (2.33%) 
46 (15.3%) 
231 (76.7%) 
17 (7.76%) 
0 (0.00%) 
 
2 (2.43%) 
19 (23.2%) 
56 (68.3%) 
5 (6.10%) 
0 (0.00%) 
 
5 (2.28%) 
27 (12.3%) 
175 (79.9%) 
12 (35.48%) 
0 (0.00%) 
 
0.114 b 
N stage 
0 
1 
 
88 (29.3%) 
213 (70.7%) 
 
58 (26.5%) 
161 (73.5%) 
 
30 (36.6%) 
52 (63.4%) 
 
0.090 b 
Initial PET CT 
FDG-avid 
FDG-negative 
 
290 (96.7%) 
11 (3.65%) 
 
75 (91.5%) 
7 (8.54%) 
 
215 (98.2%) 
4 (1.83%) 
 
0.011b 
Initial PET-CT scanner 
1 
2 
NA 
 
142 (47.7%) 
159 (52.3%) 
0 (0.00%) 
 
38 (46.3%) 
44 (55.7%) 
 
104 (47.5%) 
115 (52.5%) 
 
0.897 b 
Restaging PET-CT 
scanner 
1 
2 
CT 
 
62 (20.6%) 
158 (52.5%) 
81 (26.9%) 
 
16 (19.5%) 
46 (56.1%) 
20 (24.4%) 
 
46 (21.0%) 
112 (51.19%) 
61 (27.9%) 
 
0.739 b 
mN stage 
0 (0 nodes) 
1 (1-2 avid nodes) 
2 (>2 avid nodes) 
NA 
 
209 (69.4%) 
54 (17.9%) 
38 (12.6%) 
0 (0.00%) 
 
54 (65.9%) 
14 (17.1%) 
14 (17.1%) 
 
155 (70.8%) 
40 (18.3%) 
24 (11.0%) 
 
0.371 b 
Impassable at EGD? 
No  
Yes 
 
278 (92.4%) 
23 (7.60%) 
 
77 (93.9%) 
5 (6.10%) 
 
201 (92.8%) 
18 (8.20%) 
 
0.633b 
Surgical approach    
Resection 
LTE 
 
200 (66.4%) 
 
12 (14.6%) 
 
156 (71.3%) 
 
0.003b 
ILE 
3 stage 
THE 
ETG 
46 (15.3%) 
10 (3.32%) 
1 (0.33%) 
44 (14.6%) 
44 (53.7%) 
5 (6.10%) 
1 (1.22%) 
20 (24.4%) 
34 (15.5%) 
5 (2.28%) 
0 (0.00%) 
24 (11.0%) 
Response to chemotherapy    
Chemotherapy 
Dual 
Triple 
 
230 (76.4%) 
71 (23.6%) 
 
48 (58.5%) 
34 (41.5%) 
 
182 (83.1%) 
37 (16.9%) 
 
2.69x10-5 b 
Days to re-staging scan 
Median; IQR; range 
82.0 (71.0-93.0) 88.5 (71.3-106.8; 43.0-167) 82.0 (71.0-91.0; 40.0-
165) 
0.036 b 
Days from scan to 
surgery Median; IQR; 
range 
24.0 (17.0-33.0) 23.0 (18.3-31.8; 5.0-52.0) 23.0 (15.0-33; 4.0-
72.0) 
0.283 b 
pTR 
No 
Yes 
 
82 (27.2%) 
219 (72.8%) 
 
NA 
 
NA 
 
NA 
mTR 
Non-avid 
CMR 
PMR 
SMD 
PMD 
NA 
 
7 (2.33%) 
48 (15.9%) 
108 (35.9%) 
43 (14.3%) 
14 (4.65%) 
81 (26.9%) 
 
5 (8.06%) 
33 (53.3%) 
20 (32.4%) 
4 (1.33%) 
0 (0.00%) 
20 (NA) 
 
2 (1.27%) 
15 (9.49%) 
88 (55.7%) 
39 (24.7%) 
14 (8.86%) 
61 (NA) 
 
5.38x10-13 b 
mNR 
No avid nodes 
CMR 
PMR/SMD/PMD 
NA 
 
138 (45.8%) 
50 (16.6%) 
32 (10.6%) 
81 (26.9%) 
 
39 (62.9%) 
21 (33.9%) 
2 (3.22%) 
20 (NA) 
 
99 (62.6%) 
29 (18.4%) 
30 (19.0%) 
61 (NA) 
 
1.23x10-4 b 
a=Mann-Witney test; b=Fisher’s exact test; NA=not applicable; GEJ=gastroesophageal junction; LTE=left 
thoracoabdominal esophagectomy; ILE=Ivor-Lewis esophagectomy; THE=transhiatal esophagectomy; ETG=extended 
total gastrectomy; CMR=complete metabolic response; PMR=partial metabolic response; SMD=stable metabolic disease; 
PMD=progressive metabolic disease; mTR=metabolic tumour response; pTR=pathological tumour response; 
mNR=metabolic nodal response 
Table 2: Baseline factors associated with pathological response to neoadjuvant 
chemotherapy: univariate and multivariate regression 
Factor Response 
Univariate OR (95% CI) p Multivariate OR  (95% CI) p 
Age (Median; IQR) 1.00 (1.00-1.00) 0.536 1.00 (1.00-1.00) 0.949 
Sex 
Female  
Male 
 
Ref 
0.90 (0.50-1.62) 
 
Ref 
0.722 
 
Ref 
0.94 (0.45-1.95) 
 
Ref 
0.859 
Cell 
AC 
SCC 
AS 
NEC 
SC 
Anaplastic 
 
Ref 
1.14 (0.56-2.32) 
NA 
NA 
NA 
NA 
 
Ref 
0.716 
NA 
NA 
NA 
NA 
 
Ref 
0.87 (0.31-2.45) 
NA 
NA 
NA 
NA 
 
Ref 
0.792 
Grade 
Well 
Moderate 
Poor 
Undifferentiated 
 
Ref 
1.77 (0.62-5.02) 
1.99 (0.71-5.58) 
NA 
 
Ref 
0.284 
0.194 
NA 
 
Ref 
1.07 (0.33-3.49) 
1.53 (0.47-4.97) 
NA 
 
Ref 
0.906 
0.477 
NA 
Site 
Proximal 1/3 
Mid 1/3 
Distal 1/3 
GOJ 1 
GOJ 2 
GOJ 3 
Multifocal 
 
NA 
Ref 
0.30 (0.10-0.91) 
0.51 (0.18-1.54) 
0.28 (0.10-0.78) 
0.68 (0.23-1.98) 
NA 
 
NA 
Ref 
0.034 
0.200 
0.015 
0.480 
NA 
 
NA 
Ref 
0.21 (0.05-0.79) 
0.34 (0.09-1.26) 
0.17 (0.04-0.69) 
0.15 (0.03-0.64) 
NA 
 
NA 
Ref 
0.021 
0.106 
0.013 
0.020 
NA 
T stage 
1 
2 
3 
4a 
 
Ref 
1.76 (0.31-10.0) 
0.83 (0.16-4.42) 
1.05 (0.15-7.27) 
 
Ref 
0.525 
0.830 
0.967 
 
Ref 
2.33 (0.34-16.0) 
0.98 (0.15-6.27) 
1.13 (0.13-10.0) 
 
Ref 
0.390 
0.986 
0.916 
N stage 
0 
1 
 
Ref 
0.64 (0.37-1.10) 
 
Ref 
0.105 
 
Ref 
0.60 (0.13-1.16) 
 
Ref 
0.129 
Passable at EGD? 
Yes 
No 
 
Ref 
0.63 (0.20-1.93) 
 
Ref 
0.416 
 
Ref 
0.50 (0.13-1.95) 
 
Ref 
0.317 
Chemotherapy 
Chemo  
Dual 
Triple 
 
Ref 
3.48 (1.97-6.14) 
 
Ref 
1.76x10-5 
 
Ref 
5.98 (2.44-14.7) 
 
Ref 
8.94x10-5 
Log time to restaging 63.9 (4.24-964) 2.66x10-3 10.8 (0.42-280) 0.152 
Log time to surgery 0.93 (0.31-2.79) 0.896 1.12 (0.29-4.33) 0.873 
PET-CT variables 
PET scanner 
1 
2 
 
Ref 
1.07 (0.64-1.79) 
 
Ref 
(0.796) 
 
Ref 
0.69 (0.36-1.32) 
 
Ref 
0.267 
mN stage 
0 
1 
2 
 
Ref 
0.94 (0.46-1.89) 
1.67 (0.80-3.48) 
 
Ref 
0.857 
0.720 
 
Ref 
1.42 (0.60-3.34) 
1.72 (0.67-4.45) 
 
Ref 
0.426 
0.261 
Log SUVmax 0.43 (0.16-1.11) 0.081 0.54 (0.15-1.92) 0.343 
Log FDG-avid length 0.90 (0.81-1.01) 0.070 0.89 (0.77-1.04) 0.145 
Subset of patients staged using second PET-CT scanner (n=155) 
SUVmean 1.47 (0.09-23.4) 0.784 1.56 (0.04-65.8) 0.814 
SUVpeak 2.53 (0.41-15.8) 0.320 1.85 (0.50-6.77) 0.356 
MTV 1.55 (0.79-3.04) 0.203 1.70 (0.66-4.39) 0.276 
TGVmax 1.53 (0.84-2.76) 0.163 1.72 (0.74-3.99) 0.230 
TGVmean 1.45 (0.86-2.44) 0.164 1.64 (0.78-3.42) 0.189 
 
a=Mann-Witney U Test; b=Fisher’s exact test; GEJ=gastroesophageal junction; FDG=flurodeoxyglucose; NA=not 
applicable; *effect sizes for subgroup with FDG-avid nodes only 
 
Table 3: Post-chemotherapy factors associated with pathological response to 
neoadjuvant chemotherapy: univariate and multivariate regression – adjusted for 
baseline variables 
Factor Response 
Univariate OR (95% 
CI) 
p Multivariate OR  (95% CI) p 
Chemotherapy 
Chemo  
Dual 
Triple 
 
Ref 
4.30 (2.16-8.55) 
 
Ref 
3.23x10-5 
 
Ref 
17.6 (4.39-70.1) 
 
Ref 
5.00x10-5 
Log time to restaging 25.1 (1.10-574) 0.044 0.32 (0.00-69.2) 0.678 
Log time to surgery 2.28 (0.57-9.07) 0.241 0.52 (0.06-4.82) 0.567 
PET-CT variables 
PET scanner 
1 
2 
 
Ref 
1.09 (0.58-2.07) 
 
Ref 
0.782 
 
Ref 
0.10 (0.02-0.55) 
 
Ref 
0.008 
Restaging PET scanner 
1 
2 
 
Ref 
1.30 (0.66-2.57) 
 
Ref 
0.446 
 
Ref 
5.24 (0.95-28.9) 
 
Ref 
0.057 
Restaging mN stage 
0 (0 avid nodes) 
1 (1-2 avid nodes) 
2 (>2 avid nodes) 
 
Ref 
0.16 (0.02-1.28) 
0.16 (0.02-1.28) 
 
Ref 
0.084 
0.084 
 
Ref 
1.07 (0.07-16.8) 
2.39 (0.18-31.6) 
 
Ref 
0.959 
0.509 
Restaging log SUVmax 2.37x10-3 (4.21x10-4-
0.01) 
6.93x10-12 3.84x10-4 (1.17x10-5-0.02) 9.89x10-6 
Restaging log avid length 0.61 (0.51-0.73) 3.80x10-8 1.01 (0.76-1.34) 0.951 
Restaging log MTL 0.03 (0.01-0.10) 3.88x10-10 0.02 (4.03x10-3-0.06) 6.19x10-9 
Subset of patients with FDG-avid nodes (n=30) 
Log nodal SUVmax 8.71 (0.01-5787) 0.514 NA NA 
Subset of patients staged using second PET-CT scanner (n=155) 
Log SUVmean 1.58x10-4 (7.51x10-6-
3.23x10-3) 
1.78x10-4 1.13x10-7 (8.55x10-12-
1.46x10-3) 
9.32x10-5 
SUVpeak 5.05x10-3 (1.81x10-4-
0.14) 
1.85x10-3 0.57 (0.39-0.84) 3.90x10-3 
Log MTV 0.28 (0.18-0.44) 0.203 0.09 (0.03-0.28) 2.03x10-5 
Log TGVmax 0.32 (0.21-0.48) 3.91x10-8 0.11 (0.04-0.31) 2.72x10-5 
Log TGVmean 0.30 (0.19-0.46) 3.27x10-8 0.10 (0.03-0.29) 2.29x10-5 
a=Mann-Witney U Test; b=Fisher’s exact test; GEJ=gastroosophageal junction; FDG=flurodeoxyglucose; NA=not 
applicable; *effect sizes for subgroup with FDG-avid nodes only 
  
Table 4: Metabolic response and other factors associated with pathological 
response to neoadjuvant chemotherapy: univariate and multivariate regression 
(patients staged and restaged using same PET scanner) – adjusted for baseline 
variables 
Factor Response 
Univariate OR (95% CI) p Multivariate OR  (95% CI) p 
Chemotherapy 
Chemo  
Dual 
Triple 
 
Ref 
4.30 (2.16-8.55) 
 
Ref 
3.23x10-5 
 
Ref 
20.3 (4.50-91.4) 
 
Ref 
8.84x10-5 
Log time to restaging 69.1 (1.86-2571) 0.022 0.22 (0.00-172) 0.658 
Log time to surgery 1.75 (0.41-7.44) 0.452 0.70 (0.06-8.36) 0.781 
PET-CT variables 
Initial / restaging PET 
scanner 
1 
2 
 
Ref 
0.87 (0.40-1.88) 
 
Ref 
0.718 
 
Ref 
0.71 (0.21-2.38) 
 
Ref 
0.580 
nMR 
Negative 
CMR 
PMR 
SMD 
PMD 
 
Ref 
1.93 (0.93-4.01) 
0.45 (0.05-3.87) 
0.27 (0.03-2.18) 
NA (NA) 
 
Ref 
0.076 
0.465 
0.219 
NA 
 
Ref 
2.01 (0.54-7.51) 
11.2 (0.64-197.3) 
1.15 (0.09-14.4) 
NA (NA) 
 
Ref 
0.300 
0.098 
0.911 
NA 
Reduction logSUVmax (%) 1.04 (1.02-1.05) 6.65x10-8 1.03 (1.01-1.06) 3.24x10-3 
Reduction avid length (%) 1.03 (1.02-1.04) 9.37x10-8 1.02 (1.00-1.03) 0.019 
Additional metrics in all patients (n=202) 
Reduction MTL (%) 1.05 (1.03-1.07) 2.86x10-6 1.11 (1.05-1.16) 1.16x10-5 
PERCIST (30.0%) 
CMR 
PMR 
S/PMD 
 
Ref 
0.10 (0.04-0.22) 
0.04 (0.01-0.14) 
 
Ref 
2.24x10-
8 
2.18x10-7 
 
Ref 
0.08 (0.02-0.32) 
0.06 (0.01-0.49) 
 
Ref 
3.53x10-5 
8.46x10-4 
MUNICON (35.0%) 
No response 
Response 
 
Ref 
5.21 (2.08-13.0) 
 
Ref 
4.22x10-
5 
 
Ref 
1.63 (0.41-6.45) 
 
Ref 
0.484 
Subset of patients staged using second PET-CT scanner (n=155) 
Reduction SUVmean (%) 1.03 (1.02-1.04) 2.25x10-8 1.05 (1.02-1.09) 1.90x10-3 
Reduction SUVpeak (%) 1.09 (1.03-1.15) 1.91x10-5 1.04 (1.02-1.05) 2.20x10-3 
Reduction MTV (%) 1.44 (1.09-1.92) 2.70x10-5 1.16 (1.07-1.25) 0.011 
Reduction TGVmax (%) 1.30 (1.12-1.52) 5.82 x10-
3 
2.31 (1.27-4.20) 2.72x10-5 
Reduction TGVmean (%) 1.23 (1.10-1.37) 3.91x10-8 1.87 (1.20-2.90) 2.29x10-5 
 
a=Mann-Witney U Test; b=Fisher’s exact test; GEJ=gastroesophageal junction; FDG=flurodeoxyglucose; NA=not 
applicable; *effect sizes for subgroup with FDG-avid nodes only; nMR=metabolic nodal desponse 
 
Table 5: Comparison of tumour and nodal metabolic response 
Tumour mNR 
response NA CMR PMR SMD PMD 
Pathological response 
pTR 39 (17.7%) 21 (9.55%) 1 (0.45%) 1 (0.45%) 0 (0.00% 
No pTR 99 (45.0%) 29 (13.2%) 12 (5.45%) 13 (5.91%) 5 (22.7%) 
Metabolic response 
NA 6 (2.73%) 1 (0.45%) 0 (0.00%) 0 (0.00%) 0 
(0.00%) 
CMR 32 (14.5%) 14 (1.82%) 1 (0.45%) 1 (0.45%) 0 
(0.00%) 
PMR 68 (30.9%) 29 (13.2%)1 8 (3.64%) 2 (0.91%) 0 
(0.00%) 
SMD 22 (9.09%) 5 (2.27%) 4 (1.82%) 10 (4.55%) 3 (1.36%) 
PMD 10 (4.55%) 1 (0.45%) 0 (0.00%) 1 (0.45%) 2 (0.91%) 
pTR=tumour pathological response; mTR=metabolic tumour response; mNR metabolic nodal response; NA=not 
applicable; CMR=complete metabolic response 
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